Larimar Therapeutics, Inc. (LRMR) Tops Q3 EPS by 1c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q3 EPS of ($0.21), $0.01 better than the analyst estimate of ($0.22).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• MIND Technology (MIND) Misses Q1 EPS by 5c